PREVAIL: A MULTINATIONAL PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ORAL MDV3100 IN CHEMOTHERAPY-NAÏVE PATIENTS WITH PROGRESSIVE METASTATIC PROSTATE CANCER WHO HAVE FAILED ANDROGEN DEPRIVATION THERAPY

The purpose of this study is to determine the benefit of enzalutamide versus placebo as assessed by overall survival and progression-free survival in patients with progressive metastatic prostate cancer who have failed androgen deprivation therapy but not yet received chemotherapy.

本研究旨在明确恩扎卢胺（enzalutamide）相较于安慰剂的治疗获益，针对经雄激素剥夺治疗（androgen deprivation therapy, ADT）失败但尚未接受化疗的进展性转移性前列腺癌患者，以总生存期（overall survival, OS）与无进展生存期（progression-free survival, PFS）作为评估指标。